|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1997-3-20
|
|
pubmed:abstractText |
This Phase I trial of ciliary neurotrophic factor (CNTF) delivered intrathecally for the treatment of patients with amyotrophic lateral sclerosis was designed to determine the safety of this new mode of administration as well as the pharmacokinetics and drug distribution.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0148-396X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
94-9; discussion 99-100
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:8971830-Activities of Daily Living,
pubmed-meshheading:8971830-Amyotrophic Lateral Sclerosis,
pubmed-meshheading:8971830-Ciliary Neurotrophic Factor,
pubmed-meshheading:8971830-Dose-Response Relationship, Drug,
pubmed-meshheading:8971830-Drug Administration Schedule,
pubmed-meshheading:8971830-Humans,
pubmed-meshheading:8971830-Infusion Pumps, Implantable,
pubmed-meshheading:8971830-Injections, Spinal,
pubmed-meshheading:8971830-Metabolic Clearance Rate,
pubmed-meshheading:8971830-Nerve Growth Factors,
pubmed-meshheading:8971830-Nerve Tissue Proteins,
pubmed-meshheading:8971830-Recombinant Proteins
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
|
|
pubmed:affiliation |
Department of Neurosurgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
